Dare Bioscience
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | 10.0m | 2.8m | 10.1m | 22.5m | 46.1m |
% growth | - | - | - | (72 %) | 259 % | 123 % | 105 % |
EBITDA | (27.4m) | (39.4m) | (31.4m) | (30.9m) | - | - | - |
% EBITDA margin | - | - | (314 %) | (1101 %) | - | - | - |
Profit | (27.4m) | (38.7m) | (30.9m) | (30.2m) | (4.4m) | (29.3m) | (24.6m) |
% profit margin | - | - | (309 %) | (1074 %) | (44 %) | (130 %) | (53 %) |
EV / revenue | - | - | 7.0x | 10.8x | 3.0x | 1.4x | 0.7x |
EV / EBITDA | -2.0x | -3.9x | -2.2x | -1.0x | - | - | - |
R&D budget | 20.8m | 30.6m | 30.0m | 21.5m | - | - | - |
R&D % of revenue | - | - | 300 % | 767 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$26.0m | Post IPO Debt | ||
N/A | $3.5m | Grant | |
$15.0m | Post IPO Equity | ||
$11.5m | Grant | ||
* | $585k | Grant | |
* | N/A | $7.0m | Post IPO Equity |
* | $2.0m | Grant | |
* | N/A | $12.0m | Post IPO Equity |
* | $750k | Grant | |
* | $22.0m | Post IPO Debt | |
Total Funding | AUD138m |
Related Content
Recent News about Dare Bioscience
EditDare Bioscience is a healthcare company dedicated to advancing innovative therapies for women's health. The company focuses on developing treatments in the areas of contraception, fertility, and sexual and vaginal health. Dare Bioscience operates in the biopharmaceutical market and primarily serves women seeking improved health outcomes and convenience in their treatment options. The business model involves identifying promising therapies, advancing them through clinical trials, and partnering with other healthcare companies for mid to late-stage development and commercialization. Revenue is generated through these partnerships and the eventual sale of approved therapies. The company's mission is to expand treatment options, improve outcomes, and facilitate convenience for women worldwide.
Keywords: women's health, contraception, fertility, sexual health, vaginal health, biopharmaceutical, clinical trials, innovative therapies, healthcare partnerships, treatment options.